Stay updated with breaking news from Routine Clinical Practice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and reduces body weight in type 2 diabetes patients after 24 weeks of treatment.
Semaglutide and its effects on glycemic control, body weight (BW), and tolerability in routine clinical practice.
During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
/PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel quantitative protein and...
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two publications in the medical journal CANCER describing results from the...